首页> 外文期刊>The annals of pharmacotherapy >Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression.
【24h】

Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression.

机译:依他普仑与西酞普兰治疗严重抑郁症的成本效益比。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Severe depression is associated with an extensive economic burden on both the patient and society. OBJECTIVE: To estimate the cost-effectiveness in Austria of escitalopram compared with citalopram in the management of severe depression (Montgomery-Asberg Depression Rating Scale score > or =30). METHODS: A decision model incorporated treatment paths and associated direct resource use (psychiatric hospitalization, medications, general practitioner and psychiatrist visits, treatment discontinuation, suicide attempts) associated with managing severe depression and the indirect cost of work absenteeism over a 6-month period. Main outcomes were clinical success (remission at 6 mo) and cost (2002 Euros equals approximately 1.25 US) of treatment. The analysis was performed from the Austrian societal and Social Healthcare Insurance System (SHIS) perspectives. Clinical input data were derived from a meta-analysis of 8-week randomized clinical trials. Costs were derived from standard Austrian price lists or from the literature. RESULTS: Six months after the start of treatment, the overall clinical success remission rate was higher for escitalopram (53.7%) than for citalopram (48.7%). From the SHIS perspective, the total expected cost per successfully treated severely depressed patient was 924 (32.1%) lower for escitalopram (2879) compared with citalopram (3803). From the societal perspective, the total expected cost per successfully treated severely depressed patient was 1369 (24.4%) lower for escitalopram (5610) than for citalopram (6979). Sensitivity analyses demonstrated that the model was robust and that, even if citalopram had no acquisition cost, escitalopram remained the dominant strategy for both perspectives. CONCLUSIONS: Treatment with escitalopram was the dominant strategy. These data suggest that escitalopram is a cost-effective antidepressant compared with citalopram in the management of severe depression in Austria.
机译:背景:严重的抑郁症会给患者和社会带来巨大的经济负担。目的:评估依他普仑与西酞普兰在奥地利治疗严重抑郁症的成本效益(蒙哥马利-阿斯伯格抑郁量表评分≥30)。方法:决策模型纳入了治疗路径和相关的直接资源使用(精神病住院,药物治疗,全科医生和精神病医生就诊,治疗中止,自杀企图),这些与管理严重抑郁症和六个月期间的旷工间接成本有关。主要结果是临床成功(6 mo缓解)和治疗费用(2002欧元约等于1.25 US)。该分析是从奥地利社会和社会医疗保险系统(SHIS)的角度进行的。临床输入数据来自对8周随机临床试验的荟萃分析。成本来自标准的奥地利价格表或文献。结果:治疗开始六个月后,依他普仑的总体临床成功缓解率(53.7%)高于西酞普兰(48.7%)。从SHIS的角度来看,与西酞普兰(3803)相比,依他普仑(2879)每位成功治疗的重度抑郁症患者的总预期成本降低了924(32.1%)。从社会角度来看,依他普仑(5610)的每位成功治疗严重抑郁症患者的总预期费用比西酞普兰(6979)低1369(24.4%)。敏感性分析表明,该模型具有鲁棒性,即使西酞普兰没有购置成本,依西酞普兰仍然是这两种观点的主要策略。结论:艾司西酞普兰治疗是主要策略。这些数据表明,与西酞普兰相比,依他普仑在奥地利严重抑郁症的治疗中是一种经济有效的抗抑郁药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号